pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
onclive·May 14·1 min read
save

Stage IV Breast Cancer Cases Rise Over Past Decade, Dana-Farber Study Shows

May 14, 2026·read at onclive ↗Neutral

A recent analysis by Dana-Farber Cancer Institute examined breast cancer diagnoses over the past ten years.

The researchers found that the number of patients diagnosed with stage IV disease has risen both in absolute terms and as a share of all breast cancer cases.

The trend suggests a growing burden of advanced breast cancer, underscoring the need for continued research and therapeutic development.

source

This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.

Original headline: “Dana-Farber Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Last Decade”

read at onclive ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Dana-Farber Cancer Institute Inc
topics
Oncology7Breast Cancer6

related stories

  • Aug 13STAT+: As young people increasingly get cancer, new fertility options are changing their futuresSTAT
  • May 12GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026onclive
  • May 8Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Canceronclive
  • May 8Giants of Cancer Care Announces the 14th Annual Class of Inducteesonclive
  • May 6Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinomaonclive